Psychometric properties of FACIT-Fatigue in systemic lupus erythematosus: a pooled analysis of three phase 3 randomised, double-blind, parallel-group controlled studies (BLISS-SC, BLISS-52, BLISS-76)

Regina Rendas-Baum, Nishtha Baranwal, Ashish V Joshi, Josephine Park, Mark Kosinski, Regina Rendas-Baum, Nishtha Baranwal, Ashish V Joshi, Josephine Park, Mark Kosinski

Abstract

Background: Fatigue is a key symptom in patients with systemic lupus erythematosus (SLE), and regulatory bodies recommend its assessment in clinical trials of SLE therapies.

Methods: This post hoc pooled analysis of the three BeLimumab In Subjects with Systemic lupus erythematosus (BLISS) Phase 3 randomised, double-blind, parallel-group controlled trials evaluated the measurement properties of the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue. Patients (N = 2520) completed the FACIT-Fatigue every 4 weeks from baseline until the end of each study period. Internal consistency, test-retest reliability, convergent validity, and ability to detect changes in SLE were evaluated for the FACIT-Fatigue.

Results: The FACIT-Fatigue showed good internal consistency reliability (Cronbach's alpha > 0.90), very good test-retest reliability (0.76 ≤ intraclass correlation coefficient ≤ 0.92), and moderate-strong convergent validity (0.49 ≤ |r| ≤ 0.86) against scale and summary measure scores from the Short Form 36 Health Survey Version 2. Correlations between FACIT-Fatigue and British Isles Lupus Assessment Group (BILAG) General/Musculoskeletal scores (0.24 ≤ |r| ≤ 0.43) supported convergent validity. Correlations between FACIT-Fatigue and the Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) scores and SLE annualised flare rate were weak but in the expected direction (ranging from - 0.02 to - 0.25). Known-groups validity testing showed that the FACIT-Fatigue can significantly discriminate between patient groups with differing scores for SELENA-SLEDAI, BILAG (General and Musculoskeletal) ratings, and Physician's Global Assessment (PGA). Patients showing improvement in PGA and meeting the BILAG responder criteria had significantly higher mean improvement in FACIT-Fatigue scores than those without improvements in either measure (Week 52 mean score difference [95% confidence interval]: - 4.0 [- 5.0, - 3.0] and -2.2 [-3.1, -1.2], respectively; both p < 0.0001). The range of important (i.e. meaningful) change in FACIT-Fatigue, based on multiple anchors, was 3-6 points.

Conclusions: The FACIT-Fatigue demonstrated adequate psychometric properties in patients with SLE. The body of evidence from the three BLISS trials (both pooled and individually) supports the FACIT-Fatigue as a reliable and valid measure of SLE-related fatigue in clinical trials.

Clinical trial identifiers: BLISS-SC (NCT01484496), BLISS-52 (NCT00424476), and BLISS-76 (NCT00410384).

Keywords: FACIT-Fatigue; Fatigue; Patient-reported outcomes; Psychometric; Quality of life; Systemic lupus erythematosus; Validity.

Conflict of interest statement

AVJ is an employee of GSK and holds shares in the company. RRB, NB and MK are employees of Optum, which received funding from GSK to conduct this study. JP was an employee of GSK at the time of the study and holds shares in the company.

References

    1. Sterling K, Gallop K, Swinburn P, et al. Patient-reported fatigue and its impact on patients with systemic lupus erythematosus. Lupus. 2014;23:124–132. doi: 10.1177/0961203313511554.
    1. Kent T, Davidson A, Newman D, Buck G, D'Cruz D. Burden of illness in systemic lupus erythematosus: Results from a UK patient and carer online survey. Lupus. 2017;26:1095–1100. doi: 10.1177/0961203317698594.
    1. Zonana-Nacach A, Roseman JM, McGwin G, Jr, et al. Systemic lupus erythematosus in three ethnic groups. VI: Factors associated with fatigue within 5 years of criteria diagnosis. LUMINA study group. LUpus in MInority populations: NAture vs nurture. Lupus. 2000;9:101–109. doi: 10.1191/096120300678828046.
    1. McElhone K, Abbott J, Teh LS. A review of health related quality of life in systemic lupus erythematosus. Lupus. 2006;15:633–643. doi: 10.1177/0961203306071710.
    1. Bakshi J, Segura BT, Wincup C, Rahman A. Unmet needs in the pathogenesis and treatment of systemic lupus erythematosus. Clin Rev Allergy Immunol. 2018;55:352–367. doi: 10.1007/s12016-017-8640-5.
    1. Ahn GE, Ramsey-Goldman R. Fatigue in systemic lupus erythematosus. Int J Clin Rheumatol. 2012;7:217–227. doi: 10.2217/ijr.12.4.
    1. Yuen HK, Cunningham MA. Optimal management of fatigue in patients with systemic lupus erythematosus: A systematic review. Ther Clin Risk Manag. 2014;10:775–786. doi: 10.2147/TCRM.S56063.
    1. US Food and Drug Administration. (2010). Guidance for industry: Systemic lupus erythematosus – developing medical products for treatment. [Available from: ].
    1. European Medicines Agency. (2015). Guidelines on clinical investigation of medicinal products for the treatment of systemic lupus erythematosus and lupus nephritis. [Available from: ].
    1. . The Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale: Summary of development and validation.
    1. Lai JS, Beaumont JL, Ogale S, Brunetta P, Cella D. Validation of the functional assessment of chronic illness therapy-fatigue scale in patients with moderately to severely active systemic lupus erythematosus, participating in a clinical trial. J Rheumatol. 2011;38:672–679. doi: 10.3899/jrheum.100799.
    1. Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62:222–233. doi: 10.1002/art.27233.
    1. Holloway L, Humphrey L, Heron L, et al. Patient-reported outcome measures for systemic lupus erythematosus clinical trials: A review of content validity, face validity and psychometric performance. Health Qual Life Outcomes. 2014;12:116. doi: 10.1186/s12955-014-0116-1.
    1. Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:721–731. doi: 10.1016/S0140-6736(10)61354-2.
    1. Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63:3918–3930. doi: 10.1002/art.30613.
    1. Stohl W, Schwarting A, Okada M, et al. Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: A fifty-two-week randomized, double-blind, placebo-controlled study. Arthritis Rheumatol. 2017;69:1016–1027. doi: 10.1002/art.40049.
    1. FDA . News release. FDA approves first treatment for pediatric patients with lupus. 2019.
    1. GlaxoSmithKline . BENLYSTA (belimumab) prescribing information. 2019.
    1. GlaxoSmithKline . Benlysta 120 mg powder for concentrate for solution for infusion summary of product characteristics. 2018.
    1. FDA . Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. 2009.
    1. Rousson V, Gasser T, Seifert B. Assessing intrarater, interrater and test-retest reliability of continuous measurements. Stat Med. 2002;21:3431–3446. doi: 10.1002/sim.1253.
    1. Diggle PJ. An approach to the analysis of repeated measurements. Biometrics. 1988;44:959–971. doi: 10.2307/2531727.
    1. Gadermann AM, Guhn M, Zumbo BD. Estimating ordinal reliability for Likert-type and ordinal item response data: A conceptual, empirical, and practical guide. Pract Assess Res Eval. 2012;17:1–13.
    1. Nunnally JaB IH. The assessment of reliability. Psychom Theory. 1994;3:248–292.
    1. Cappelleri JC, Zou KH, Bushmakin AG, et al. Patient-reported outcomes: Measurement, implementation and interpretation. Boca Raton: Chapman & Hall/CRC Press; 2013.
    1. Diggle PJ, Heagerty PJ, Liang K-Y, Zeger SL. Analysis of longitudinal data. 2. Oxford: Oxford University Press; 2002.
    1. Weckerle CE, Niewold TB. The unexplained female predominance of systemic lupus erythematosus: Clues from genetic and cytokine studies. Clin Rev Allergy Immunol. 2011;40:42–49. doi: 10.1007/s12016-009-8192-4.
    1. Chalmers RP. On misconceptions and the limited usefulness of ordinal alpha. Educ Psychol Meas. 2018;78:1056–1071. doi: 10.1177/0013164417727036.
    1. Agresti A. Categorical data analysis. 2. Hoboken: Wiley; 2003.
    1. Sijtsma K. On the use, the misuse, and the very limited usefulness of Cronbach's alpha. Psychometrika. 2009;74:107–120. doi: 10.1007/s11336-008-9101-0.
    1. Haldorsen K, Bjelland I, Bolstad AI, Jonsson R, Brun JG. A five-year prospective study of fatigue in primary Sjogren's syndrome. Arthritis Res Ther. 2011;13:R167. doi: 10.1186/ar3487.
    1. Miyamoto, S. T., Paganotti, M. A., Serrano, E. V., Giovelli, R. A., & Valim, V. (2015). Assessment of fatigue and dryness in primary Sjogren's syndrome: Brazilian version of "Profile of Fatigue and Discomfort - Sicca Symptoms Inventory (Short Form) (PROFAD-SSI-SF)". Rev Bras Reumatol, 55, 113–122.
    1. Miyamoto ST, Valim V, Carletti L, et al. Supervised walking improves cardiorespiratory fitness, exercise tolerance, and fatigue in women with primary Sjogren's syndrome: A randomized-controlled trial. Rheumatol Int. 2019;39:227–238. doi: 10.1007/s00296-018-4213-z.
    1. Cella, D., Wilson, H., Shalhoub, H., et al. (2019). Content validity and psychometric evaluation of Functional Assessment of Chronic Illness Therapy-Fatigue in patients with psoriatic arthritis. J Patient Rep Outcomes, 3, 30.
    1. Cella, D., Yount, S., Sorensen, M., et al. (2005). Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. J Rheumatol, 32, 811–819.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner